Logo
x

Search

Subscribe Now

Ascletis

Ascletis Reports Positive Interim Results from the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B Functional Cure

Ascletis Reports Positive Interim Results from the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B Functiona...

  • September 29, 2023
Ascletis Reports the Dosing of Four Healthy Patients of ASC11 in Multiple-Dose Escalation P-I Trial for COVID-19

Ascletis Reports the Dosing of Four Healthy Patients of ASC11 in Multiple-Dose Escalation P-I Trial for COVID-19

  • January 16, 2023
Ascletis’ ASC11 Receives the US FDA’s IND Approval for the Treatment COVID-19

Ascletis’ ASC11 Receives the US FDA’s IND Approval for the Treatment COVID-19

  • November 24, 2022
Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

Ascletis Reports Patients Dosing in Multiple-Dose Escalation P-I Clinical Trial of ASC10 for COVID-19

  • October 10, 2022
Ascletis Reports First Patient Dosing in the P-II Clinical Trial of ASC41 for Liver Biopsy-Proven Non-Alcoholic Steatohepatitis

Ascletis Reports First Patient Dosing in the P-II Clinical Trial of ASC41 for Liver Biopsy-Proven Non-Alcoholic Steatohepatitis

  • October 5, 2022
Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

Ascletis Reports First Patient Dosing in the P-IIb Expansion Cohort of ASC22 (envafolimab) for Chronic Hepatitis B

  • September 29, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.